Dental implant surgery in patients in treatment by dabigatran

Abstract

Dental implant surgery in patients taking dabigatran can be performed safely providing 12 h have passed since the last dose and local hemostatic measures are applied. Normal dosage can be resumed 8 h after implant surgery.

World workshop on oral medicine VII: Direct anticoagulant agents management for invasive oral procedures: A systematic review and meta‐analysis

“…None of the included studies was a randomized controlled trial (RCT). Nine articles were prospective case–control studies (Andrade et al., ; Berton et al., ; Caliskan, Tükel, Benlidayi, & Deniz, ; Clemm et al., ; Gómez‐Moreno et al., , ; Mauprivez et al., ; Miclotte et al., ; Miranda et al., ), four were retrospective case–control studies (Hanken et al., ; Kwak et al., ; Lababidi et al., ; Yagyuu et al., ), and five studies were retrospective (Johnston, ; Miller & Miller, ; Morimoto, Yokoe, Imai, Sugihara, & Futatsuki, ; Zeevi et al., ) and prospective (Patel et al., ) observational studies, reporting data from medical records. Three studies were case‐series (Abayon, Kolokythas, Siu, & Elad, ; Breik, Cheng, Sambrook, & Goss, ; Hassona, Malamos, Shaqman, Baqain, & Scully, ).…”

“…The majority of studies reported the use of different local hemostatic measures, apart from sutures, to control bleeding during the oral procedures. In brief, measures used included gelatin sponges or foam (Abayon et al., ; Lababidi et al., ; Mauprivez et al., ), cellulose (Andrade et al., ; Berton et al., ; Breik et al., ; Caliskan et al., ; Hassona et al., ; Lababidi et al., ; Morimoto et al., ; Zeevi et al., ), tranexamic acid (Berton et al., ; Gómez‐Moreno et al., , ; Hassona et al., ), and a combination of all these measures (Tables and ).…”

“…Of the six studies, one study was assessed as good quality, four were evaluated as fair quality, and one of poor quality (Table ). Risk of bias of the 21 studies was assessed using the Newcastle‐Ottawa scale: two studies received a low risk of bias score (seven stars, Miller & Miller, ; Zeevi et al., ), 16 studies received a high risk of bias score (six stars, Andrade et al., ; Berton et al., ; Caliskan et al., ; Clemm et al., ; Gómez‐Moreno et al., , ; Hanken et al., ; Kwak et al., ; Lababidi et al., ; Mauprivez et al., ; Miclotte et al., ; Miranda et al., ; Morimoto et al., ; Patel et al., ; Yagyuu et al., and five stars, Johnston, ), and three case‐series received a very high risk of bias score (one star, Abayon et al., ; Breik et al., ; Hassona et al., ; Table ).…”

Review: An overview and analysis of novel oral anticoagulants and their dental implications

“…Gomez et al aimed to evaluate the incidence of bleeding complications following dental implant therapy in 71 patients . In this study, 29 patients had been taking dabigatran for at least 6 months prior to implant surgery and 42 patients composed a healthy control group .…”

“…29 In this study, 29 patients had been taking dabigatran for at least 6 months prior to implant surgery and 42 patients composed a healthy control group. 29 In the dabigatran group, patients were treated with implant placement 12 hours after the last dose of dabigatran; these patients resumed dabigatran dosing 8 hours after the procedure. 29 Results of this study indicated that no statistical difference existed in the number of bleeding complications between the dabigatran group and the control group.…”